Renal Cell Carcinoma Treatment Options

• Treatment for renal cell carcinoma is individualized, based on the tumor’s stage and grade, the kidney’s remaining function, and the patient’s overall health and preferences.
• Nephrectomy — an operation that removes part or all of the affected kidney — is the main treatment for localized renal cell carcinoma; a partial, kidney-sparing version is used when the tumor and its location allow.
• For advanced or metastatic disease, targeted therapy and immunotherapy — not standard chemotherapy — are the main systemic treatments used against renal cell carcinoma.
• Immune checkpoint inhibitors, sometimes combined with each other or with a targeted therapy (such as ipilimumab plus nivolumab), are part of standard first-line treatment for advanced disease.
• A multidisciplinary care team helps weigh the benefits and risks of each option, and clinical trials can offer additional treatment paths for eligible patients.

Understanding Renal Cell Carcinoma Treatment

Renal cell carcinoma (RCC) treatment has moved away from a single standard approach toward plans built around each patient, since the disease can behave differently from person to person. Treatment strategies are tailored to the tumor’s characteristics, the stage of disease, and the patient’s overall health, and treatment goals can range from curing the cancer to controlling its growth and managing symptoms in order to support quality of life.

Compared with many other cancers, standard chemotherapy plays little role in treating renal cell carcinoma. The National Cancer Institute lists surgery, radiation therapy, immunotherapy, and targeted therapy as the main treatment types used for this disease, and for advanced cases targeted therapy and immunotherapy are typically the systemic treatments of choice. A team that may include urologists, oncologists, radiation oncologists, and pathologists works together to build the most appropriate plan for each patient.

Surgical and Localized Therapies for RCC

For many patients with localized renal cell carcinoma, surgery is the primary treatment. These procedures aim to remove the cancerous tissue while preserving as much healthy kidney function as possible.

Nephrectomy (Partial vs. Radical)

Nephrectomy refers to an operation that removes part or all of a kidney affected by cancer. The National Cancer Institute describes three main approaches — partial, simple, and radical nephrectomy — and the choice depends on the tumor’s size and location and how well the kidneys are functioning.

• Partial Nephrectomy: Removes only the cancer and a margin of surrounding kidney tissue, sparing the rest of the kidney. This kidney-sparing approach can help maintain overall kidney function, an important consideration for patients whose remaining kidney is impaired or who no longer have a second kidney.
• Simple Nephrectomy: Removes the kidney alone, without taking the adjacent adrenal gland and tissue that a radical procedure includes.
• Radical Nephrectomy: Removes the whole kidney along with the adrenal gland if cancer is present there, plus nearby fatty tissue and lymph nodes. This approach is generally chosen for larger tumors or when kidney-sparing surgery isn’t appropriate, and it can be curative for patients whose disease is limited to the kidney.

Ablation and Radiation Therapy

For patients who are not good candidates for surgery because of other health conditions, or for smaller tumors, localized options such as ablation may be considered. Cryotherapy freezes and destroys the tumor, while thermal ablation uses heat; both are typically guided by imaging and used mainly for people who cannot safely have surgery.

External beam radiation therapy is also used to treat renal cell carcinoma, most often as palliative care to relieve symptoms — such as bone pain from cancer that has spread — and to improve quality of life. A precise method called stereotactic ablative body radiation therapy may be used in certain cases, and radiation can also be given before or after surgery for some larger or more extensive tumors.

Systemic Therapies: Targeted & Immunotherapy

When renal cell carcinoma has spread beyond the kidney or cannot be removed surgically, systemic therapy becomes the main approach. For RCC this typically means targeted therapy or immunotherapy rather than traditional chemotherapy, since these approaches have driven most of the recent gains in treating advanced disease.

Targeted Therapy Approaches

Targeted therapies interfere with specific molecules that cancer cells need to grow and spread, rather than affecting rapidly dividing cells throughout the body the way traditional chemotherapy does. Many of the targeted drugs used for renal cell carcinoma, including sunitinib and pazopanib, work in part by blocking signals that trigger new blood vessel formation, which tumors rely on to grow; other targeted drugs used for RCC interfere with different cell-growth signals. These are typically oral medications used for advanced disease.

Immunotherapy for Kidney Cancer

Immunotherapy works by helping the immune system recognize and attack cancer cells, rather than acting on the tumor directly. Immune checkpoint inhibitors are the main type of immunotherapy used for renal cell carcinoma; they block checkpoint proteins — such as PD-1, PD-L1, or CTLA-4 — that cancer cells use to turn down the immune response, which allows T cells to attack the tumor more effectively.

For advanced renal cell carcinoma, immunotherapy drugs may be used alone or combined — ipilimumab plus nivolumab is one option used as initial treatment — or paired with a targeted therapy. These combinations are part of standard first-line treatment for advanced disease rather than an experimental approach, and have been linked to better outcomes than older single-drug regimens.

Emerging Renal Cell Carcinoma Treatments

Research into renal cell carcinoma continues, with studies exploring new drug combinations, additional treatment targets, and approaches guided by a tumor’s genetic profile. Clinical trials give eligible patients access to treatments not yet widely available and remain an option worth discussing with a care team. The latest developments in this research are covered in more depth elsewhere on this site.

Factors Guiding RCC Treatment Decisions

Deciding on the right treatment for renal cell carcinoma means weighing several factors together, so the chosen approach fits both the cancer and the person being treated.

Disease Stage and Grade

The stage and grade of renal cell carcinoma are central to treatment planning. Stage describes how far the cancer has spread — including tumor size, lymph node involvement, and whether it has reached other organs — while grade reflects how abnormal the cancer cells look under a microscope.

Disease Stage	Characteristics	Typical Treatment Approach
Stage I	Tumor is 7 cm or smaller and found in the kidney only.	Partial, simple, or radical nephrectomy; if surgery is not an option, cryotherapy, thermal ablation, or stereotactic body radiation therapy may be used.
Stage II	Tumor is larger than 7 cm but still confined to the kidney.	Partial or radical nephrectomy; for cancer at higher risk of returning, radical nephrectomy may be followed by pembrolizumab.
Stage III	Cancer of any size in the kidney has reached nearby lymph nodes, major nearby veins, or the layer of fat surrounding the kidney.	Radical nephrectomy, sometimes preceded by arterial embolization to limit blood loss during surgery; may be followed by pembrolizumab or sunitinib, or paired with radiation for more extensive tumors.
Stage IV	Cancer has spread beyond the fatty tissue around the kidney, into the adrenal gland, or to distant organs such as the lungs, bone, or liver.	Targeted therapy and immunotherapy, often combined (for example, ipilimumab plus nivolumab), are the main first-line options; nephrectomy may still be used in select cases to relieve symptoms or reduce tumor size.

Higher-stage, higher-grade renal cell carcinoma generally calls for more intensive or systemic treatment, though the exact plan still depends on each patient’s individual case.

Patient Health and Preferences

Beyond the cancer itself, a patient’s overall health — including age, other medical conditions, and general fitness — affects which treatments are appropriate. Someone with significant other health issues may not be a good candidate for extensive surgery or certain systemic therapies because of the added risks.

Patient preferences matter too. Shared decision-making means being fully informed about the benefits and risks of each option, so the chosen path reflects personal goals and quality-of-life priorities alongside the medical recommendation.

Frequently Asked Questions

What is the primary treatment for early-stage renal cell carcinoma?

Surgery is typically the primary treatment for early-stage renal cell carcinoma, often a partial nephrectomy that removes only the cancerous portion of the kidney while preserving healthy tissue and kidney function. When partial removal is not feasible, a radical nephrectomy that removes the whole kidney may be used instead. The choice depends on the tumor’s characteristics and the patient’s overall health.

How do targeted therapy and immunotherapy differ in treating RCC?

Targeted therapy blocks specific signals cancer cells rely on to grow, such as those that trigger new blood vessel formation. Immunotherapy instead helps the body’s own immune system recognize and attack cancer cells, often through immune checkpoint inhibitors. Both are used for advanced renal cell carcinoma, sometimes together, but they work through different biological mechanisms.

Are there new treatments on the horizon for kidney cancer?

Yes — research continues into new drug combinations and treatment targets for renal cell carcinoma, and clinical trials are one way patients can access these newer approaches. Ask your care team whether a clinical trial might be a good fit for your situation.

Sources

• National Cancer Institute – Renal Cell Cancer Treatment (PDQ®)–Patient Version
• National Cancer Institute – Immune Checkpoint Inhibitors
• National Cancer Institute – Targeted Therapy to Treat Cancer